AP NEWS

Nexstim Plc supports 10th International Symposium on Navigated Brain Stimulation in Neurosurgery and Neuromodulation

September 28, 2018

Press release, Helsinki, 28 th September 2018 at 9:00 AM EEST

Nexstim Plc supports 10th International Symposium on Navigated Brain Stimulation in Neurosurgery and Neuromodulation

Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, today announces its support for the 10th International Symposium on Navigated Brain Stimulation (NBS) which will be held on 12-13 October 2018 in Berlin, Germany.

The symposium attracts a wide international audience from Europe, US and Asia and provides an update on Navigated Transcranial Magnetic Stimulation (nTMS) for both therapy and brain mapping by leaders in their respective fields.

The keynote lecture will be given by Professor Johannes Schramm, former chairman of neurosurgery from the Medical School of the University of Bonn. Professor Schramm played an essential role in the clinical development and introduction of intraoperative neurophysiological monitoring and mapping for the resection of brain tumors.

Professor Peter Vajkoczy and Professor Bernhard Meyer, the two chairmen of the two hosting neurosurgical departments, will give an insight into their own experience and how they developed their approach working with nTMS data in clinical routine.

Professor Alvaro Pascual-Leone from Harvard Medical School and Professor Jean-Pascal LeFaucheur, from the Paris-Est Créteil University will hold presentations on the therapeutic use of navigated transcranial magnetic stimulation (TMS).

Professor LeFaucheur is the corresponding author of the European guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Professor Pascual-Leone is one of the world leaders in the development of transcranial magnetic stimulation in cognitive neuroscience and for therapeutic applications in neurology, psychiatry, and neurorehabilitation.

Nexstim’s system for navigated brain stimulation (NBS) will be showcased at the symposium. It is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Martin Jamieson, Chairman and CEO, Nexstim Plc said: “We are pleased to support this symposium that has established its place as an important meeting for the experts in the field of navigated brain stimulation. The symposium has repeatedly attracted a large international audience to discuss the latest developments in the field. This also indicates growing international interest across physicians in the use of TMS in neurosurgery and in the treatment of depression and pain.

The symposium is organised by Charité - Universitätsmedizin Berlin and Klinikum rechts der Isar, TU München and supported by Nexstim.

***

Further information is available on the website www.nexstim.com or by contacting:

Nexstim +44 771 516 3942Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com

Citigate Dewe Rogerson +44 (0)207 2822949David Dible/ Shabnam Bashir/ Sylvie Berrebi nexstim@citigatedewerogerson.com

About Nexstim Plc Nexstim is a medical technology company focused on the development and commercialization of its world-leading SmartFocusTM TMS technology, a non-invasive brain stimulation system for the treatment of Major Depressive Disorder (MDD). The Company’s proprietary Navigated Brain Therapy (NBT®) system, a highly sophisticated 3D navigation, is the only personalised, navigated transcranial magnetic stimulation (TMS) approach providing accurate targeting of the TMS to the specific area of the brain associated with MDD.

Nexstim’s NBT® system has been launched in the US for the treatment of MDD following clearance from the FDA for marketing and commercial distribution for this indication. The NBT® system is CE marked in Europe for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercialising its Navigated Brain Stimulation (NBS) system for diagnostic applications, based on the same technology. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Attachment

-- Nexstim Plc NBS Symposium.pdf

AP RADIO
Update hourly